Catalyst Biosciences Inc has issued two million shares priced at $34 a share through an underwritten public offering to raise $100m.
The underwriters have a 30-day option to buy an additional 441,176 shares.
The US-based clinical-stage biopharmaceutical company plans to use proceeds for general corporate purposes, including clinical activities and production of CB 2679d and Marzeptacog alfa.
Catalyst Biosciences has appointed Jones Trading Institutional Services LLC as book-running manager and LifeSci Capital LLC as lead manager for the transaction.
Bermuda-based biopharmaceutical company Poxel SA has issued one million ordinary shares each priced at $10.41 a share through a private placement to raise $14.9m.
Swiss-based Roivant Sciences Ltd is subscribed to the placement.
The companies have simultaneously signed a strategic development and licensing agreement for the Poxel’s type 2 diabetes treatment, Imeglimin, in the US, Europe, and other countries.
Underwriters will be granted a 30-day option to buy additional shares.
The US-based biopharmaceutical company plans to use the proceeds towards phase II clinical trials of BXCL501 and general corporate purposes.
German biopharmaceutical company Affimed NV plans to raise $23m through a public offering of 11 million shares of its common stock priced at $2 a share.
Underwriters will have a 30-day option to buy 1.7 million additional shares.
The company plans to use proceeds for funding clinical and pre-clinical research and development (R&D) activities and other general corporate purposes.
Qrons Inc has issued 312,500 shares of its common stock priced at $1.60 a share through a private placement to raise $500,000.
The US-based biotechnology company plans to use the proceeds for conducting research and for other general corporate purposes.
Australian life sciences company Invion Ltd has agreed to issue 1.2 million shares priced at A$0.02 ($0.02) a share through a rights offering to raise A$2.5m ($1.95m).
The company will use proceeds for general working capital and debt repayment.
CHO Group has been appointed as the underwriter for the transaction, which is scheduled to be complete by March 2018.